Ciuleanu TE et al. Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study. Proc ASCO 2008;Abstract 8011.

Gatzemeier U et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation trial. J Clin Oncol 2007;25(12):1545-52. Abstract

Hainsworth J et al. A phase III, multicenter, placebo-controlled, double-blind, randomized clinical trial to evaluate the efficacy of bevacizumab (Avastin®) in combination with erlotinib (Tarceva®) compared with erlotinib alone for treatment of advanced non-small cell lung cancer after failure of standard first-line chemotherapy (BETA). Proc Multidisciplinary Symposium in Thoracic Oncology 2008;Abstract LBA1.

Herbst RS et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer. J Clin Oncol 2007;25(30):4743-50. Abstract

Herbst RS et al. TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combinedwith carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23(25):5892-9. Abstract

Manegold C et al. (AVAIL): A Phase III randomised study of first-line bevacizumab combined with cisplatin/gemcitabine in patients with advanced or recurrent non-squamous, non-small-cell-lung cancer. Proc ESMO 2008;Abstract LBA1.

Mok T et al. Phase III, randomised, open-label, first-line study of gefitinib (G) vs carboplatin/ paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small-cell lung cancer (NSCLC) (IPASS). Proc ESMO 2008;Abstract LBA2.

Patel JD et al. Pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for advanced non-squamous non-small cell lung cancer (NSCLC). Proc ASCO 2008;Abstract 8044

Pirker R et al. FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) Proc ASCO 2008;Abstract 3.

Ramalingam SS et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: Analysis of Eastern Cooperative Oncology Group trial 4599. J Clin Oncol 2008;26(1):60-5. Abstract

Sandler AB et al. Retrospective study of clinical and radiographic risk factors associated with early onset, severe pulmonary hemorrhage in bevacizumab-treated patients with advanced non-small cell lung cancer (NSCLC). Proc ASCO 2008;Abstract 8074.

Sandler A et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-50. Abstract

Scagliotti GV et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26(21):3543-51. Abstract